Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG005 plus gigaxitinib hydrochloride in advanced non-small cell lung cancer
CTR20251061Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig, gigaxitinib in non-small cell lung cancer (NSCLC), sponsored by Zelgen. Started May 2025; status: active.
02
Drugs
nilvanstomiggigaxitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251061.